



Forbion Capital Partners leads €9.6 Million Expansion Financing of Curetis AG

The Unyvero™ Solution: next level molecular diagnostic solutions for fast & reliable infectious disease testing

Munich, Germany, 26 October 2011 – Forbion Capital Partners, the Dutch life sciences venture capital firm, today announces that it has led the expansion financing of the Series A round of Curetis AG together with Roche Venture Fund, CD-Venture and management.

Curetis has developed a diagnostics platform to identify the pathogen that causes a patient's pneumonia and which antibiotic resistance patterns are present within a few hours. It will allow physicians to diagnose the cause of the infection faster and commence the appropriate targeted antibiotic regimen immediately in critically ill patients. The platform is very robust and versatile and can be used for other molecular diagnostics applications as well.

Since its inception in 2007, Curetis AG has developed the *Unyvero™* instrument platform handling disease specific disposable cartridges for the analysis of various marker panels, covering both pathogens and antibiotic resistance genes. The work flow of the *Unyvero™* platform is fully automated, practical to use and enables testing at the point of need, eliminating operator-induced variations and ensures high-quality results in a short time frame. The first application for pneumonia testing has successfully finalized extensive pre-clinical testing and is about to enter into pivotal clinical trials with the aim of entering the European market as a CE-marked device in 2012.

Holger Reithinger, Partner at Forbion Capital Partners, said: "There is an urgent unmet medical need for faster identification of pathogens and resistance markers due to increasing antibiotic resistance and even multidrug resistance. With pneumonia, most current diagnostics are still relying on culture-based technologies, which can take days to deliver results. Curetis' technology platform will reduce this timeline to hours. The company is led by an experienced diagnostics industry management team, which has built the company from the start. I am looking forward to helping to make this a commercial success." Holger Reithinger has joined Curetis' Board of Directors.

Oliver Schacht, CEO of Curetis added: "We are pleased to have Forbion leading our expanded series A financing and Roche Venture Fund joining as a new investor. These two investors will bring additional molecular diagnostics expertise to the table and will significantly strengthen our investor syndicate for the upcoming corporate development phases. I am also delighted that CD-Venture increased their commitment to Curetis and have taken the opportunity myself to invest at this exciting stage of Curetis' development. We are now well funded for the upcoming clinical trials as well as our planned 2012 European market launch of the Unyvero platform and pneumonia application."

-Ends-

For more information, please contact:

Forbion Capital Partners

Holger Reithinger
Tel. +49 172 252 9032
Tel. +49 89 41 61 61 950
hr@forbion.com

College Hill Life Sciences (on behalf of Forbion)

Melanie Toyne Sewell / Anastasios Koutsos
+44 20 7866 7856
forbion@collegehill.com

Curetis

Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 (0) 7031 49195-10
pr@curetis.com
www.curetis.com

Media Inquiries (for Curetis):

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

Notes to Editors:

About Curetis (Germany)

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG will enable rapid multiparameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised total funds of over € 36.6 million (~ USD 50 million). The company is based in Holzgerlingen near Stuttgart, Germany.

About Forbion Capital Partners

Forbion Capital Partners is a dedicated Life Sciences venture capital firm with offices in Naarden, The Netherlands, and Munich, Germany. Forbion invests in life sciences companies, particularly in world-class drug discovery & development as well as med tech and diagnostics companies addressing substantial unmet medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea, PanGenetics and BioVex. Current assets under management exceed EUR 400M, split between three active funds and comprising some 28 promising portfolio companies. Forbion Capital Partners Fund II is supported by the European Investment Fund through its ERP and LfA facilities. Finally, Forbion co-manages Biogeneration Ventures, an early stage fund focused on (academic) spin-outs and seed investments in the Netherlands.

For more information, please visit www.forbion.com.